Quick Takeaways
- Lynx1 Capital Management LP filed SCHEDULE 13G/A for C4 Therapeutics, Inc. Common Stock, $0.0001 par value per share (CCCC).
- Disclosed ownership: 7.3%.
- Date of event: 31 Dec 2025.
Lynx1 Capital Management LP - 31 Dec 2025 SCHEDULE 13G/A Report for C4 Therapeutics, Inc. Common Stock, $0.0001 par value per share (CCCC)
- Filing Manager
- Lynx1 Capital Management LP
- Reporting Manager
- Lynx1 Capital Management LP
- Symbol
- CCCC
- Shares outstanding
- 97,234,699 shares
- Disclosed Ownership
- 7,098,133 shares
- Ownership
- 7.3%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 13:45:15 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Lynx1 Capital Management LP disclosed 7.3% ownership in C4 Therapeutics, Inc. Common Stock, $0.0001 par value per share (CCCC) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Feb 2026, 13:45.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 7.3% | 7,098,133 | 0 | 7,098,133 | /s/ Weston Nichols | By: Lynx1 Capital Management GP LLC, General Partner, By: Weston Nichols, Sole Member | |
| Weston Nichols | 7.3% | 7,098,133 | 0 | 7,098,133 | /s/ Weston Nichols | Weston Nichols, Individually |